Fármacos para tratamento da COVID-19: À espera da evidência

Translated title of the contribution: Medicines for the treatment of COVID-19: Awaiting the evidence

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)
515 Downloads (Pure)


The novel severe acute respiratory syndrome coronavirus 2 is the cause of Coronavirus Disease 2019, a new illness with no effective treatment or vaccine that has reached pandemic proportions. In this document, we analyze how health authorities and agencies around the world position themselves regarding the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019. We review the most promising candidate medicines, including available evidence, clinical recommendations and current options for access. Our concluding remarks stress the importance of administering off-label and investigational drugs in the setting of clinical trials, or at least in standardized scenarios, to generate as much scientific knowledge as achievable while engaging in the best efforts to treat patients and save lives.

Translated title of the contributionMedicines for the treatment of COVID-19: Awaiting the evidence
Original languagePortuguese
Pages (from-to)500-504
Number of pages5
JournalActa Médica Portuguesa
Issue number7-8
Publication statusPublished - Jul 2020


  • Coronavirus
  • Coronavirus Infections/drug therapy
  • COVID-19/drug therapy


Dive into the research topics of 'Medicines for the treatment of COVID-19: Awaiting the evidence'. Together they form a unique fingerprint.

Cite this